IP Library Granted Patent US 10,487,137
Granted Patent B2
US 10,487,137 · App. 15/837,569 · Granted Nov 26, 2019

Method for improving antibody

Inventors: Masaharu Torikai (Kumamoto, JP); Toshihiro Nakashima (Kikuchi, JP)
Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
C07K16/00C07K16/1271C07K16/2818C07K2317/21C07K2317/24C07K2317/567C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,487,137
App. No.
15/837,569
Granted
Nov 26, 2019
Kind
B2
Abstract

The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.

Claims (10)

1. A method for improving the expression level and/or stability of a human antibody or a humanized antibody, said method comprising:

modifying a human antibody or a humanized antibody by substituting proline at position 12 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of the human antibody or the humanized antibody with a different amino acid other than proline selected from any one of the amino acid substitutions: Ser, His, Val, Gly, Leu, Arg, Phe, Met or Glu, wherein said VL chain belongs to human Vκ2 family and has a framework FR1, which prior to substitution, has the FR1 sequence encoded by SEQ ID:32 from DPK18 (GeneBank Accession No. X63403), to thereby obtain a modified human antibody or a modified humanized antibody having improved expression level and/or stability as compared to a control, which is identical to the human antibody or the humanized antibody but without said substitution.

2. The method according to claim 1 , wherein the FR1 of the VL chain belonging to human Vx2 family after substitution has the amino acid sequence selected from the amino acid sequences as depicted in SEQ ID NO: 9 to 17.

3. The method according to claim 1 , wherein said antibody is an intact antibody, or an antibody fragment such as Fab, Fab′, F(ab′)2, scAb, scFv, diabody [a recombinant dimer antibody consisting of homologous or heterologous heavy chain variable region (VH chain) and VL chain connected by a short linker peptide] or scFv-Fc; or a fused antibody or a fused antibody fragment with other proteins; or an antibody or an antibody fragment labeled with a low molecular weight compound; or an antibody or an antibody fragment modified with a high molecular weight compound.

4. The method according to claim 1 , wherein the amino acid substitution is done by a genetic recombination technique.

5. A method for preparing an antibody with an improved expression level and/or stability according to claim 1 , comprising:

preparing a gene coding for an amino acid sequence of said human antibody or said humanized antibody or a fragment of said human or humanized antibody, each comprising the amino acid sequence of the VL chain after substitution;

transforming a host of eukaryotic or prokaryotic organisms with said gene;

expressing said human antibody or said humanized antibody or said human antibody fragment or said humanized antibody fragment from said host; and

recovering said human antibody or said humanized antibody or said human antibody fragment or said humanized antibody fragment.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: TORIKAI, MASAHARU; NAKASHIMA, TOSHIHIRO
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 044356/0659 →
CHANGE OF NAME Recorded Dec 11, 2017
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 044829/0386 →